LABORATORY CORP OF AMERICA HOLDINGS

Form 10-Q November 02, 2006

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

| (Mark One) þ | One) | | | | | | | | | |
|---|---|--------------------------------------|--|--|--|--|--|--|--|--|
| For the quarterly period ended <u>September 30, 2006</u> | | | | | | | | | | |
| | | OR | | | | | | | | |
| " TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE 1934 | | | | | | | | | | |
| | For the transition po | eriod from to | | | | | | | | |
| | Commission file number <u>1-11353</u> | | | | | | | | | |
| | LABORATORY CORPORATION OF AMERICA HOLDINGS | | | | | | | | | |
| | (Exact name of registrant as | specified in its charter) | | | | | | | | |
| | Delaware | 13-3757370 | | | | | | | | |
| (State | or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | | | | | | | | |
| | 358 South Main Street, Burlington, North Carolina | 27215 | | | | | | | | |
| | (Address of principal executive offices) | (Zip Code) | | | | | | | | |
| | | 1. (224) 220 1128 | | | | | | | | |

(Registrant's telephone number, including area code) (336) 229-1127

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes b No "

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated file. See definition of "accelerated filer" and "large accelerated filer" in Rule 12b-2 of the Exchange Act.

Large accelerated filer b Accelerated filer Non-accelerated filer

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act. Yes "No b

The number of shares outstanding of the issuer's common stock is 125.4 million shares, net of treasury stock as of October 30, 2006.

INDEX

PART I. FINANCIAL INFORMATION

Item 1 Financial Statements:

<u>Condensed Consolidated Balance Sheets</u> <u>September 30, 2006 and December 31, 2005</u>

<u>Condensed Consolidated Statements of Operations</u>
<u>Three and nine month periods ended September 30, 2006 and 2005</u>

<u>Condensed Consolidated Statements of Changes in Shareholders</u> <u>Equity Nine months ended September 30, 2006 and 2005</u>

Condensed Consolidated Statements of Cash Flows Nine months ended September 30, 2006 and 2005

Notes to Unaudited Condensed Consolidated Financial Statements

Item 2 <u>Management s Discussion and Analysis of</u>

Financial

Condition and Results of Operations

Item 3 Quantitative and Qualitative Disclosures about Market Risk

Item 4 Controls and Procedures

PART II. OTHER INFORMATION

Item 1 <u>Legal Proceedings</u>

Item 1A Risk Factors

Item 2 <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>

Item 6 Exhibits

2

PART I FINANCIAL INFORMATION

Item 1. Financial Statements

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS

(in millions) (unaudited)

| | September 30, 2006 | December 31, 2005 | | |
|--|-----------------------|----------------------|--|--|
| ASSETS | | | | |
| Current assets: | | | | |
| Cash and cash equivalents | \$ 8.6 | \$ 45.4 | | |
| Short-term investments | 312.1 | 17.7 | | |
| Accounts receivable, net | 567.8 | 493.4 | | |
| Supplies inventories | 75.5 | 65.4 | | |
| Prepaid expenses and other | 43.9 | 37.2 | | |
| Deferred income taxes | 25.6 | 43.2 | | |
| Total current assets | 1,033.5 | 702.3 | | |
| Property, plant and equipment, net | 371.9 | 381.5 | | |
| Goodwill, net | 1,473.2 | 1,477.0 | | |
| Intangible assets, net | 611.8 | 645.7 | | |
| Investments in joint venture partnerships | 598.7 | 578.9 | | |
| Other assets, net | 76.3 | 90.4 | | |
| Total assets | \$ 4,165.4 | \$ 3,875.8 | | |
| LIABILITIES AND SHAREHOLDERS' EQUITY | | | | |
| Current liabilities: | | | | |
| Accounts payable | \$ 129.3 | \$ 116.2 | | |
| Accrued expenses and other | 221.5 | 227.3 | | |
| Short term borrowings and current portion of long-term debt | 552.7 | 544.6 | | |
| Total current liabilities | 903.5 | 888.1 | | |
| Long-term debt, less current portion | 603.1 | 604.5 | | |
| Deferred income taxes | 427.2 | 408.9 | | |
| Other liabilities | 86.6 | 88.6 | | |
| Total liabilities | 2,020.4 | 1,990.1 | | |
| Commitments and contingent liabilities | | | | |
| Shareholders' equity: Common stock, 125.4 and 126.5 shares outstanding at | | | | |
| September 30, 2006 and December 31, 2005, respectively | 14.7 | 14.8 | | |
| Additional paid-in capital | 1,253.3 | 1,339.7 | | |
| Retained earnings | 1,664.2 | 1,336.3 | | |
| Less common stock held in treasury | (891.6) | (888.5) | | |
| Unearned restricted stock compensation | | (6.9) | | |
| Accumulated other comprehensive earnings | 104.4 | 90.3 | | |
| | | | | |

| | September 30, | December 31, |
|--|---------------|--------------|
| Total liabilities and shareholders' equity | \$ 4,165.4 | \$ 3,875.8 |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in millions, except per share data) (unaudited)

| Three Months Ended | Nine Months Ended |
|---------------------------|-------------------|
| September 30, | September 30, |
| | |

| | <u> </u> | 11001 50, | September 50, | | | | | | | |
|---|----------|-----------|---------------|------------|--|--|--|--|--|--|
| | 2006 | 2005 | 2006 | 2005 | | | | | | |
| Net sales | \$ 909.9 | \$ 852.9 | \$ 2,692.2 | \$ 2,505.3 | | | | | | |
| Cost of sales | 525.0 | 498.3 | 1,541.8 | 1,447.5 | | | | | | |
| Gross profit | 384.9 | 354.6 | 1,150.4 | 1,057.8 | | | | | | |
| Selling, general and | | | | | | | | | | |
| and administrative expenses | 194.9 | 179.9 | 576.0 | 527.2 | | | | | | |
| Amortization of intangibles | 13.0 | 13.1 | 39.0 | 38.3 | | | | | | |
| Restructuring and other special charges | 1.0 | 10.0 | 1.0 | 10.0 | | | | | | |
| Operating income | 176.0 | 151.6 | 534.4 | 482.3 | | | | | | |
| Other income (expenses): | | | | | | | | | | |
| Investment loss | | | | (3.1) | | | | | | |
| Interest expense | (11.9) | (8.4) | (35.4) | (25.5) | | | | | | |
| Income from joint venture | | | | | | | | | | |
| partnerships | 16.3 | 13.8 | 49.6 | 41.4 | | | | | | |
| Investment income | 2.8 | 0.4 | 4.4 | 1.2 | | | | | | |
| Other, net | (0.1) | | (1.9) | (0.2) | | | | | | |
| Earnings before income taxes | 183.1 | 157.4 | 551.1 | 496.1 | | | | | | |
| Provision for income taxes | 73.5 | 62.7 | 223.2 | 198.8 | | | | | | |
| Net earnings | \$ 109.6 | \$ 94.7 | \$ 327.9 | \$ 297.3 | | | | | | |
| Basic earnings per | | | | | | | | | | |
| common share | \$ 0.88 | \$ 0.71 | \$ 2.63 | \$ 2.21 | | | | | | |
| common snarc | Ψ 0.00 | φ 0.71 | Ψ 2.03 | ψ 2.21 | | | | | | |
| Diluted earnings per | | | | | | | | | | |
| common share | \$ 0.81 | \$ 0.66 | \$ 2.43 | \$ 2.07 | | | | | | |
| | | | | | | | | | | |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

LABORATORY CORPORATION OF AMERICA HOLDINGS AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY (in millions) (unaudited)

| | ommon Stock | Additional Paid-in Capital | | Retained Earnings | | Treasury Stock | | Unearned Restricted Stock ompensation | Co | Other Other Omprehensive Earnings | Total Shareholders' Equity |
|--|----------------|--------------------------------------|----|----------------------|----|-------------------|----|--|----|--|----------------------------------|
| BALANCE AT DECEMBER 31, 2004 | \$ 15.1 | \$ 1,504.1 | \$ | 950.1 | \$ | (544.2) | \$ | (7.5) | \$ | 81.7 | \$ 1,999.3 |
| Comprehensive earnings: Net earnings Other comprehensive earnings: | | | | 297.3 | | | | | | | 297.3 |
| Foreign currency translation adjustments Tax effect of other | | | | | | | | | | 14.7 | 14.7 |
| comprehensive earnings adjustments | | | | | | | | | | (6.1) | (6.1) |
| Comprehensive earnings Issuance of common stock under | 0.2 | 52.2 | | | | | | | | | 305.9 |
| employee stock plans Issuance of restricted stock awards | 0.2 | 53.3 7.2 | | | | | | (7.2) | | | 53.5 |
| Surrender of restricted stock awards Cancellation of restricted stock | | | | | | (7.3) | | | | | (7.3) |
| awards | | (0.3) | | | | | | 0.3 | | | |
| Stock compensation Income tax benefit from stock options exercised | | 3.9 10.0 | | | | | | 5.9 | | | 9.8 10.0 |
| Purchase of common stock | | | _ | | _ | (200.9) | _ | | _ | | (200.9) |
| BALANCE AT SEPTEMBER 30, 2005 | \$ 15.3 | \$ 1,578.2 | \$ | 1,247.4 | \$ | (752.4) | \$ | (8.5) | \$ | 90.3 | \$ 2,170.3 |
| BALANCE AT DECEMBER 31, 2005 Comprehensive earnings: Net earnings | \$ 14.8 | \$ 1,339.7 | \$ | 1,336.3 327.9 | \$ | (888.5) | \$ | (6.9) | \$ | 90.3 | \$ 1,885.7 |